Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Kindlin-1 Promotes Pulmonary Breast Cancer Metastasis.

Sarvi S, Patel H, Li J, Dodd GL, Creedon H, Muir M, Ward J, Dawson JC, Lee M, Culley J, Salter DM, Sims AH, Byron A, Brunton VG.

Cancer Res. 2018 Mar 15;78(6):1484-1496. doi: 10.1158/0008-5472.CAN-17-1518. Epub 2018 Jan 12.

2.

Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.

Creedon H, Gómez-Cuadrado L, Tarnauskaitė Ž, Balla J, Canel M, MacLeod KG, Serrels B, Fraser C, Unciti-Broceta A, Tracey N, Le Bihan T, Klinowska T, Sims AH, Byron A, Brunton VG.

Oncotarget. 2016 Mar 8;7(10):11539-52. doi: 10.18632/oncotarget.7317.

3.

Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer.

Creedon H, Balderstone LA, Muir M, Balla J, Gomez-Cuadrado L, Tracey N, Loane J, Klinowska T, Muller WJ, Brunton VG.

Dis Model Mech. 2016 Feb;9(2):131-40. doi: 10.1242/dmm.023143. Epub 2015 Dec 31.

4.

Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.

Creedon H, Byron A, Main J, Hayward L, Klinowska T, Brunton VG.

Biochem Soc Trans. 2014 Aug;42(4):822-30. doi: 10.1042/BST20140109. Review.

PMID:
25109964
5.

Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.

Karim SA, Creedon H, Patel H, Carragher NO, Morton JP, Muller WJ, Evans TR, Gusterson B, Sansom OJ, Brunton VG.

J Pathol. 2013 Aug;230(4):430-40. doi: 10.1002/path.4202.

PMID:
23616343
6.

Src kinase inhibitors: promising cancer therapeutics?

Creedon H, Brunton VG.

Crit Rev Oncog. 2012;17(2):145-59. Review.

PMID:
22471705

Supplemental Content

Loading ...
Support Center